ABSI News

Latest breaking news and updates for ABSI stock.

Track all markets on TradingView

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia. World-renowned experts will guide...

What are the expected short‑term and long‑term financial impacts on ABSI's valuation and stock price from this development? What is the potential market size for a hair loss treatment and how does ABS-201 compare to existing or pipeline competitors? How will the addition of Dr. Sinclair and Dr. Goldberg to the advisory board affect the timeline and likelihood of success for ABS-201's clinical trials?
Clinical trials
about 13 hours ago
Read more globenewswire

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half...

What are the implications for the company's capital structure and leverage ratios moving forward? Could the extended cash runway alter the company's strategic timeline or partnership opportunities? What is the market's perception of the balance sheet strengthening—does it reduce risk premiums for the stock?
Earnings
14 days ago
Read more globenewswire

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABS...

What is the likely impact on the share volume and volatility for both Almirall (ALM) and Absci (ABSI) in the short term? How might this expanded collaboration affect the competitive landscape for existing dermatology treatments? Are there any contingent or performance‑based clauses in the partnership that might trigger additional financial obligations?
Collaboration
19 days ago
Read more globenewswire